Fig. 9

“Visual field” enlargement according to study timepoints (T0, T1, T2) in the eye treated with WJ-MSCs. Note the change in FPDI and MD values (Table 1, patient 2: left eye—published data: a and b are the first 6-month changes of a patient from our previous study [46]). a Before application, FPDI 6%—MD 28.03. b At 6th month, FPDI 16%—MD 26.61. c At 12th month, FPDI 19%—MD 23.45